Most cited papers from Probity Medical Research

Probity Medical Research

What are the most cited papers from Probity Medical Research?

The most cited paper from Probity Medical Research is "Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials" (Richard G B Langley, Boni Elizabeth Elewski, Mark Lebwohl et al., 2014), with 2,004 citations. Next come "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)" (1,876) and "Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)" (1,365).

Published TypeFieldAccessAuthorsCitations

Showing 50 of 60 papers. Every paper with more than 263 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials Richard G B Langley, Boni Elizabeth Elewski, Mark Lebwohl et al. · New England Journal of Medicine Open access	9 Jul 2014	2,004
2	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Craig L. Leonardi, Alexa B. Kimball, Kim Alexander Papp et al. · The Lancet	May 2008	1,876
3	Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Kim Alexander Papp, Richard G B Langley, Mark Lebwohl et al. · The Lancet	May 2008	1,365
4	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial Andrew Blauvelt et al. · The Lancet Open access	4 May 2017	1,269
5	Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial Stephen Keith Tyring, Alice Bendix Gottlieb, Kim Alexander Papp et al. · The Lancet	22 Dec 2005	1,075
6	Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial Kristian Reich, Frank Oliver Nestle, Kim Alexander Papp et al. · The Lancet	Oct 2005	1,049
7	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics Alan Menter et al. · Journal of the American Academy of Dermatology	13 Feb 2019	970
8	Brodalumab, an Anti–Interleukin-17–Receptor Antibody for Psoriasis Kim Alexander Papp, Craig L. Leonardi, Alan Menter et al. · New England Journal of Medicine	28 Mar 2012	941
9	Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial Andrew Blauvelt, Kim Alexander Papp, Christopher E.M. Griffiths et al. · Journal of the American Academy of Dermatology Open access	4 Jan 2017	898
10	Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial Alan Menter, Stephen Keith Tyring, Kenneth B. Gordon et al. · Journal of the American Academy of Dermatology	3 Dec 2007	892
11	Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque Psoriasis Kenneth B. Gordon, Andrew Blauvelt, Kim Alexander Papp et al. · New England Journal of Medicine Open access	8 Jun 2016	855
12	Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials Christopher E.M. Griffiths, Kristian Reich, Mark Lebwohl et al. · The Lancet	13 Jun 2015	842
13	Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis Mark Lebwohl et al. · New England Journal of Medicine Open access	30 Sep 2015	826
14	Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa Alexa B. Kimball et al. · New England Journal of Medicine	3 Aug 2016	804
15	Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION) J.‐H. Saurat, George Stingl, Louis Dubertret et al. · British Journal of Dermatology Open access	28 Nov 2007	729
16	A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction Kim Alexander Papp, Stephen Keith Tyring, Mourad Lahfa et al. · British Journal of Dermatology	Jun 2005	697
17	Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials Kenneth B. Gordon, Bruce E Strober, Mark Lebwohl et al. · The Lancet	Aug 2018	681
18	Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1) Kim Alexander Papp, Kristian Reich, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology Open access	16 Jun 2015	680
19	Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)* Andreas Wollenberg et al. · British Journal of Dermatology Open access	Oct 2020	627
20	Golimumab, a new human tumor necrosis factor α antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty‐four–week efficacy and safety results of a randomized, placebo‐controlled study Arthur Kavanaugh, Iain B. McInnes, Philip J. Mease et al. · Arthritis & Rheumatism	30 Mar 2009	605
21	A Novel Targeted T-Cell Modulator, Efalizumab, for Plaque Psoriasis Mark Lebwohl, Stephen Keith Tyring, Tiffani K. Hamilton et al. · New England Journal of Medicine Open access	19 Nov 2003	582
22	Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials Emma Guttman‐Yassky, Henrique D. Teixeira, Eric Lawrence Simpson et al. · The Lancet	20 May 2021	574
23	Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial Diamant Thaçi et al. · The Lancet	20 Oct 2015	573
24	Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled, phase 3 trials Kristian Reich, Kim Alexander Papp, Andrew Blauvelt et al. · The Lancet	6 Jun 2017	565
25	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis Eric Lawrence Simpson et al. · JAMA Dermatology Open access	6 Nov 2019	519
26	A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis Alan Menter, Steven R. Feldman, Gerald D. Weinstein et al. · Journal of the American Academy of Dermatology	7 Sep 2006	518
27	Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis Kim Alexander Papp, Andrew Blauvelt, Michael Bukhalo et al. · New England Journal of Medicine Open access	19 Apr 2017	516
28	Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics Philip J. Mease, Dafna D. Gladman, Kim Alexander Papp et al. · Journal of the American Academy of Dermatology	24 Aug 2013	511
29	Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: Double-blind, randomized controlled trial and open-label extension study Kenneth B. Gordon, Richard G B Langley, Craig L. Leonardi et al. · Journal of the American Academy of Dermatology	11 Aug 2006	510
30	Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis Andrew Blauvelt, Henrique D. Teixeira, Eric Lawrence Simpson et al. · JAMA Dermatology Open access	4 Aug 2021	504
31	Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities Craig A. Elmets et al. · Journal of the American Academy of Dermatology	13 Feb 2019	503
32	A prospective phase III, randomized, double‐blind, placebo‐controlled study of brodalumab in patients with moderate‐to‐severe plaque psoriasis Kim Alexander Papp, Kristian Reich, Carle F. Paul et al. · British Journal of Dermatology Open access	25 Feb 2016	470
33	Increase in TNF-α and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a) Michelle Anne Lowes, Francesca Chamian, Maria Veronica Abello et al. · Proceedings of the National Academy of Sciences Open access	27 Dec 2005	454
34	Bimekizumab versus Secukinumab in Plaque Psoriasis Kristian Reich, Richard Bruce Warren, Mark Lebwohl et al. · New England Journal of Medicine	23 Apr 2021	427
35	Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis Kim Alexander Papp, Kenneth B. Gordon, Diamant Thaçi et al. · New England Journal of Medicine Open access	12 Sep 2018	424
36	Topical tofacitinib for atopic dermatitis: a phase II a randomized trial Robert Bissonnette, Kim Alexander Papp, Yves P. Poulin et al. · British Journal of Dermatology Open access	16 Jul 2016	422
37	Long-term safety of ustekinumab in patients with moderate-to-severe psoriasis: final results from 5 years of follow-up Kim Alexander Papp, Christopher E.M. Griffiths, Kenneth B. Gordon et al. · British Journal of Dermatology	10 Jan 2013	415
38	Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis Jonathan I. Silverberg, Eric Lawrence Simpson, Jacob Pontoppidan Thyssen et al. · JAMA Dermatology Open access	3 Jun 2020	405
39	Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children Ulrich Wahn, Jan Dositheus Bos, Mark J. D. Goodfield et al. · PEDIATRICS	Jul 2002	405
40	Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial Hervé Bachelez, Peter C.M. van de Kerkhof, Robert Strohal et al. · The Lancet Open access	6 Jun 2015	403
41	Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial Amy S. Paller et al. · Journal of the American Academy of Dermatology Open access	20 Jun 2020	399
42	Efalizumab for Patients With Moderate to Severe Plaque Psoriasis Kenneth B. Gordon, Kim Alexander Papp, Tiffani K. Hamilton et al. · JAMA	16 Dec 2003	397
43	Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial April Wang Armstrong, Melinda Gooderham, Richard Bruce Warren et al. · Journal of the American Academy of Dermatology Open access	9 Jul 2022	371
44	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial Emma Guttman‐Yassky, Diamant Thaçi, Aileen L. Pangan et al. · Journal of Allergy and Clinical Immunology Open access	28 Nov 2019	365
45	Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study Kim Alexander Papp, Richard G B Langley, Bárður Sigurgeirsson et al. · British Journal of Dermatology	27 Oct 2012	361
46	A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis Gerald G. Krueger, Kim Alexander Papp, Dow B. Stough et al. · Journal of the American Academy of Dermatology	25 Nov 2002	348
47	Dupilumab: A review of its use in the treatment of atopic dermatitis Melinda Gooderham, Hwanhee Hong, Panteha Eshtiaghi et al. · Journal of the American Academy of Dermatology	19 Feb 2018	343
48	Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a Phase 2b randomized placebo-controlled dose-ranging study Kim Alexander Papp, Alan Menter, Bruce E Strober et al. · British Journal of Dermatology	27 Aug 2012	339
49	Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials Kim Alexander Papp, Alan Menter, Mai Abe et al. · British Journal of Dermatology Open access	7 Jul 2015	328
50	Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial* Jonathan I. Silverberg, D. Toth, Thomas R.M. Bieber et al. · British Journal of Dermatology Open access	Oct 2020	327

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.